Notably, TNFR2 has emerged as a key player in T cell activation and is thought to contribute to the tumor’s strategy to evade immune responses, a phenomenon often referred to as the tumor’s counterattack (129). The gene discussed is TNFRSF1B; the disease is neoplasm.